Expression of cyclooxygenase‑2 and mucin 1 in colorectal cancer

Abstract

In colorectal cancer (CRC), pathological factors that correlate with negative prognosis include, among others, overexpression of cyclooxygenase-2 (COX-2) and abundant expression of mucin 1 (MUC1). COX-2 overexpression may therefore be associated with MUC1 overexpression. The aim of the present study was to investigate the possible correlation between COX-2 and MUC1 expression and to assess the correlation between their individual expression and the clinicopathological features of patients, paying particular attention to survival. The following data was collected from the 170 patients with CRC included in the present study: Age, sex, tumour localization, disease stage and survival. Tumour samples were immunostained with antibodies against COX-2 and MUC1. Protein expression was scored, relative to reference staining, and correlated with the clinicopathological data of patients. The results revealed no correlation between the expressions of COX-2 and MUC1, or with any of the studied clinicopathological variables. In addition, the expression of the two proteins were not associated. Neither of the proteins demonstrated prognostic value for survival. The present study did not confirm a direct relationship between the expressions of COX-2 and MUC1, or between the expression of either protein and the clinicopathological features of patients, including survival.

High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement

“…6 These findings are consistent with the research of Gipsyianti et al, which revealed high COX-2 immunoexpression in acral melanoma; Szlendak et al on colorectal adenocarcinoma; and Liu et al on renal cell carcinoma. 3,20,21 The results of the present show a significant association between COX-2 immunoexpression and the occurrence of metastases in ccRCC (p=0.001) with a POR of 10.28. These results indicate that ccRCC patients with high COX-2 immunoexpression are ten-times as likely to be associated with metastases as ccRCC patients with low COX-2 immunoexpression.…”

“…6 These findings are consistent with the research of Gipsyianti et al, which revealed high COX-2 immunoexpression in acral melanoma; Szlendak et al on colorectal adenocarcinoma; and Liu et al on renal cell carcinoma. 3 , 20 , 21 …”

The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days

“… 28 The overexpression of MUC1 was directly associated with the apoptosis pathway 29 and gastric cancer, 30 indicating it could be considered a high-risk factor for the prognosis of gastrointestinal carcinoma. Szlendak et al 31 reported that decreased expression of MUC2 secreted gel-forming mucin is generally observed in colorectal adenocarcinoma, while increased expression of MUC1 was observed in colorectal cancer, indicating low oral doses of BaP could alter MUC expression via colonic injury. Moreover, acute villous injury and atrophy with edema fluid accumulation in the lumen, the mononuclear cells, inflammatory cells, and multifocal cells in the stomach and the colon of mice were investigated following oral intake of BaP for 60 days, suggesting these altered expressions could be contributed to early cancer development risk potential.…”

ATG16L2 overexpression is associated with a good prognosis in colorectal cancer

“…In recent years, histochemistry and molecular biology have rapidly developed, and a large number of predictive prognostic markers have been identified (7). Immunohistochemistry of tumor tissues can provide an objective predictive value by which to assess prognosis (8). At present, CRC is initially diagnosed by CT, endoscopy, and measurement of tumor serum markers such as carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 125 (9).…”